These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9027536)

  • 1. Risk factors for invasive Haemophilus influenzae disease among children 2-16 years of age in the vaccine era, Switzerland 1991-1993. The Swiss H. Influenzae Study Group.
    Mühlemann K; Alexander ER; Weiss NS; Pepe M; Schopfer K
    Int J Epidemiol; 1996 Dec; 25(6):1280-5. PubMed ID: 9027536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disappearance of epiglottitis during large-scale vaccination with Haemophilus influenzae type B conjugate vaccine among children in Finland.
    Takala AK; Peltola H; Eskola J
    Laryngoscope; 1994 Jun; 104(6 Pt 1):731-5. PubMed ID: 8196448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum antibodies against haemophilus influenzae type b and tetanus at 2.5 years of age: a follow-up of 2 different regimens of infant vaccination.
    Carlsson RM; Claesson BA; Lagergård T; Käyhty H
    Scand J Infect Dis; 1996; 28(5):519-23. PubMed ID: 8953685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of conjugated PRP vaccines on the incidence of invasive diseases caused by Haemophilus influenzae Type B in childhood].
    Desgrandchamps D; Schmid R; Zimmermann HP; Imahorn P; Kabus K; Schubiger G
    Schweiz Med Wochenschr; 1994 Apr; 124(14):575-82. PubMed ID: 8184297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children.
    CMAJ; 1993 Jan; 148(2):199-214. PubMed ID: 8452591
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era.
    Heath PT; Booy R; Azzopardi HJ; Slack MP; Fogarty J; Moloney AC; Ramsay ME; Moxon ER
    Pediatr Infect Dis J; 2001 Mar; 20(3):300-5. PubMed ID: 11303834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued shortage of Haemophilus influenzae Type b (Hib) conjugate vaccines and potential implications for Hib surveillance--United States, 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(46):1252-5. PubMed ID: 19023262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age.
    Loughlin AM; Marchant CD; Lett S; Shapiro ED
    Pediatr Infect Dis J; 1992 May; 11(5):374-9. PubMed ID: 1630857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.
    Anderson EL; Decker MD; Englund JA; Edwards KM; Anderson P; McInnes P; Belshe RB
    JAMA; 1995 Mar; 273(11):849-53. PubMed ID: 7869554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive Haemophilus influenzae disease in Utah children: an 11-year population-based study in the era of conjugate vaccine.
    Bender JM; Cox CM; Mottice S; She RC; Korgenski K; Daly JA; Pavia AT
    Clin Infect Dis; 2010 Apr; 50(7):e41-6. PubMed ID: 20178414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP.
    Harris A; Hendrie D; Bower C; Payne J; de Klerk N; Stanley F
    Med J Aust; 1994 Apr; 160(8):483-8. PubMed ID: 8170423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children.
    Adegbola RA; Mulholland EK; Secka O; Jaffar S; Greenwood BM
    J Infect Dis; 1998 Jun; 177(6):1758-61. PubMed ID: 9607866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study.
    Adegbola RA; Secka O; Lahai G; Lloyd-Evans N; Njie A; Usen S; Oluwalana C; Obaro S; Weber M; Corrah T; Mulholland K; McAdam K; Greenwood B; Milligan PJ
    Lancet; 2005 Jul 9-15; 366(9480):144-50. PubMed ID: 16005337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term trends in invasive Haemophilus influenzae type B disease among indigenous Australian children following use of PRP-OMP and PRP-T vaccines.
    Menzies RI; Bremner KM; Wang H; Beard FH; McIntyre PB
    Pediatr Infect Dis J; 2015 Jun; 34(6):621-6. PubMed ID: 25973940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
    Bewley KM; Schwab JG; Ballanco GA; Daum RS
    Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.